The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

• DOI: 10.1002/cac2.12218
• Publication Date: 2021-10-26T18:30:08Z
• Authors: Ling‐Long Tang; Yu‐Pei Chen; Chuan‐Ben Chen; Ming‐Yuan Chen; Nian‐Yong Chen; Xiao‐Zhong Chen; Xiao‐Jing Du; Wen‐Feng Fang; Mei Feng; Jin Gao; Fei Han; Xia He; Chao‐Su Hu; De‐sheng Hu; Guang‐Yuan Hu; Hao Jiang; Wei Jiang; Feng Jin; Jin‐Yi Lang; Jin‐Gao Li; Shao‐Jun Lin; Xu Liu; Qiu‐Fang Liu; Lin Ma; Hai‐Qiang Mai; Ji‐Yong Qin; Liang‐Fang Shen; Ying Sun; Pei‐Guo Wang; Ren‐Sheng Wang; Ruo‐Zheng Wang; Xiao‐Shen Wang; Ying Wang; Hui Wu; Yun‐Fei Xia; Shao‐Wen Xiao; Kun‐Yu Yang; Jun‐Lin Yi; Xiao‐Dong Zhu; Jun Ma
• Keywords: Risk; China; Staging; Nasopharyngeal Carcinoma; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Guidelines and Consensus; Nasopharyngeal Neoplasms; Medical Oncology; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; CSCO; Diagnosis; Nasopharyngeal carcinoma; Humans; Chinese Society of Clinical Oncology; RC254-282

AbstractNasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi‐disciplinary team comprising of experts from all sub‐specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence‐based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow‐up of NPC, which aim to improve the management of NPC.